Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of erythromycin on palbociclib pharmacokinetics
2018-004032-29Phase 4Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of palbociclib and erythromycin in breast cancer and cancer, sponsored by Netherlands Cancer Institute. Primary endpoints: Palbociclib AUC0-24h, Palbociclib Cmax and 1 more. Started Nov 2018; status: completed.
02
Drugs
palbocicliberythromycin
03
Conditions
breast cancercancer
Beyond the preview
Go deeper on 2018-004032-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004032-29.